This is important clinically, as drugs that inhibit BCR-signaling also cause CLL cells to move out of the lymph nodes into the peripheral blood resulting in an increased lymphocytosis [80]. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.